HEATR1 negatively regulates akt to help sensitize pancreatic cancer cells to chemotherapy

Tongzheng Liu, Yuan Fang, Haoxing Zhang, Min Deng, Bowen Gao, Nifang Niu, Jia Yu, Seung Baek Lee, Jung Jin Kim, Bo Qin, Fang Xie, Debra Evans, Liewei M Wang, Wenhui Lou, Zhenkun Lou

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Elucidating mechanisms of chemoresistance is critical to improve cancer therapy, especially for the treatment of pancreatic ductal adenocarcinoma (PDAC). Genome-wide association studies have suggested the less studied gene HEAT repeat-containing protein 1 (HEATR1) as a possible determinant of cellular sensitivity to different chemotherapeutic drugs. In this study, we assessed this hypothesized link in PDAC, where HEATR1 expression is downregulated significantly. HEATR1 silencing in PDAC cells increased resistance to gemcitabine and other chemotherapeutics, where this effect was associated with increased AKT kinase phosphorylation at the Thr308 regulatory site. Mechanistically, HEATR1 enhanced cell responsiveness to gemcitabine by acting as a scaffold to facilitate interactions between AKT and the protein phosphatase PP2A, thereby promoting Thr308 dephosphorylation. Consistent with these findings, treatment with the AKT inhibitor triciribine sensitized HEATR1-depleted PDAC cells to gemcitabine, suggesting that this therapeutic combination may overcome gemcitabine resistance in patients with low HEATR1 expression. Clinically, we found that HEATR1 downregulation in PDAC patients was associated with increased AKT phosphorylation, poor response to tumor resection plus gemcitabine standard-of-care treatment, and shorter overall survival. Collectively, our findings establish HEATR1 as a novel regulator of AKT and a candidate predictive and prognostic indicator of drug responsiveness and outcome in PDAC patients.

Original languageEnglish (US)
Pages (from-to)572-581
Number of pages10
JournalCancer Research
Volume76
Issue number3
DOIs
StatePublished - Feb 1 2016

Fingerprint

gemcitabine
Pancreatic Neoplasms
Drug Therapy
Adenocarcinoma
Proteins
triciribine
Down-Regulation
Phosphorylation
Therapeutics
Genome-Wide Association Study
Phosphoprotein Phosphatases
Standard of Care
Pharmaceutical Preparations
Neoplasms
Phosphotransferases
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HEATR1 negatively regulates akt to help sensitize pancreatic cancer cells to chemotherapy. / Liu, Tongzheng; Fang, Yuan; Zhang, Haoxing; Deng, Min; Gao, Bowen; Niu, Nifang; Yu, Jia; Lee, Seung Baek; Kim, Jung Jin; Qin, Bo; Xie, Fang; Evans, Debra; Wang, Liewei M; Lou, Wenhui; Lou, Zhenkun.

In: Cancer Research, Vol. 76, No. 3, 01.02.2016, p. 572-581.

Research output: Contribution to journalArticle

Liu, T, Fang, Y, Zhang, H, Deng, M, Gao, B, Niu, N, Yu, J, Lee, SB, Kim, JJ, Qin, B, Xie, F, Evans, D, Wang, LM, Lou, W & Lou, Z 2016, 'HEATR1 negatively regulates akt to help sensitize pancreatic cancer cells to chemotherapy', Cancer Research, vol. 76, no. 3, pp. 572-581. https://doi.org/10.1158/0008-5472.CAN-15-0671
Liu, Tongzheng ; Fang, Yuan ; Zhang, Haoxing ; Deng, Min ; Gao, Bowen ; Niu, Nifang ; Yu, Jia ; Lee, Seung Baek ; Kim, Jung Jin ; Qin, Bo ; Xie, Fang ; Evans, Debra ; Wang, Liewei M ; Lou, Wenhui ; Lou, Zhenkun. / HEATR1 negatively regulates akt to help sensitize pancreatic cancer cells to chemotherapy. In: Cancer Research. 2016 ; Vol. 76, No. 3. pp. 572-581.
@article{fa48dad302f94ee190805985c05940be,
title = "HEATR1 negatively regulates akt to help sensitize pancreatic cancer cells to chemotherapy",
abstract = "Elucidating mechanisms of chemoresistance is critical to improve cancer therapy, especially for the treatment of pancreatic ductal adenocarcinoma (PDAC). Genome-wide association studies have suggested the less studied gene HEAT repeat-containing protein 1 (HEATR1) as a possible determinant of cellular sensitivity to different chemotherapeutic drugs. In this study, we assessed this hypothesized link in PDAC, where HEATR1 expression is downregulated significantly. HEATR1 silencing in PDAC cells increased resistance to gemcitabine and other chemotherapeutics, where this effect was associated with increased AKT kinase phosphorylation at the Thr308 regulatory site. Mechanistically, HEATR1 enhanced cell responsiveness to gemcitabine by acting as a scaffold to facilitate interactions between AKT and the protein phosphatase PP2A, thereby promoting Thr308 dephosphorylation. Consistent with these findings, treatment with the AKT inhibitor triciribine sensitized HEATR1-depleted PDAC cells to gemcitabine, suggesting that this therapeutic combination may overcome gemcitabine resistance in patients with low HEATR1 expression. Clinically, we found that HEATR1 downregulation in PDAC patients was associated with increased AKT phosphorylation, poor response to tumor resection plus gemcitabine standard-of-care treatment, and shorter overall survival. Collectively, our findings establish HEATR1 as a novel regulator of AKT and a candidate predictive and prognostic indicator of drug responsiveness and outcome in PDAC patients.",
author = "Tongzheng Liu and Yuan Fang and Haoxing Zhang and Min Deng and Bowen Gao and Nifang Niu and Jia Yu and Lee, {Seung Baek} and Kim, {Jung Jin} and Bo Qin and Fang Xie and Debra Evans and Wang, {Liewei M} and Wenhui Lou and Zhenkun Lou",
year = "2016",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-15-0671",
language = "English (US)",
volume = "76",
pages = "572--581",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - HEATR1 negatively regulates akt to help sensitize pancreatic cancer cells to chemotherapy

AU - Liu, Tongzheng

AU - Fang, Yuan

AU - Zhang, Haoxing

AU - Deng, Min

AU - Gao, Bowen

AU - Niu, Nifang

AU - Yu, Jia

AU - Lee, Seung Baek

AU - Kim, Jung Jin

AU - Qin, Bo

AU - Xie, Fang

AU - Evans, Debra

AU - Wang, Liewei M

AU - Lou, Wenhui

AU - Lou, Zhenkun

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Elucidating mechanisms of chemoresistance is critical to improve cancer therapy, especially for the treatment of pancreatic ductal adenocarcinoma (PDAC). Genome-wide association studies have suggested the less studied gene HEAT repeat-containing protein 1 (HEATR1) as a possible determinant of cellular sensitivity to different chemotherapeutic drugs. In this study, we assessed this hypothesized link in PDAC, where HEATR1 expression is downregulated significantly. HEATR1 silencing in PDAC cells increased resistance to gemcitabine and other chemotherapeutics, where this effect was associated with increased AKT kinase phosphorylation at the Thr308 regulatory site. Mechanistically, HEATR1 enhanced cell responsiveness to gemcitabine by acting as a scaffold to facilitate interactions between AKT and the protein phosphatase PP2A, thereby promoting Thr308 dephosphorylation. Consistent with these findings, treatment with the AKT inhibitor triciribine sensitized HEATR1-depleted PDAC cells to gemcitabine, suggesting that this therapeutic combination may overcome gemcitabine resistance in patients with low HEATR1 expression. Clinically, we found that HEATR1 downregulation in PDAC patients was associated with increased AKT phosphorylation, poor response to tumor resection plus gemcitabine standard-of-care treatment, and shorter overall survival. Collectively, our findings establish HEATR1 as a novel regulator of AKT and a candidate predictive and prognostic indicator of drug responsiveness and outcome in PDAC patients.

AB - Elucidating mechanisms of chemoresistance is critical to improve cancer therapy, especially for the treatment of pancreatic ductal adenocarcinoma (PDAC). Genome-wide association studies have suggested the less studied gene HEAT repeat-containing protein 1 (HEATR1) as a possible determinant of cellular sensitivity to different chemotherapeutic drugs. In this study, we assessed this hypothesized link in PDAC, where HEATR1 expression is downregulated significantly. HEATR1 silencing in PDAC cells increased resistance to gemcitabine and other chemotherapeutics, where this effect was associated with increased AKT kinase phosphorylation at the Thr308 regulatory site. Mechanistically, HEATR1 enhanced cell responsiveness to gemcitabine by acting as a scaffold to facilitate interactions between AKT and the protein phosphatase PP2A, thereby promoting Thr308 dephosphorylation. Consistent with these findings, treatment with the AKT inhibitor triciribine sensitized HEATR1-depleted PDAC cells to gemcitabine, suggesting that this therapeutic combination may overcome gemcitabine resistance in patients with low HEATR1 expression. Clinically, we found that HEATR1 downregulation in PDAC patients was associated with increased AKT phosphorylation, poor response to tumor resection plus gemcitabine standard-of-care treatment, and shorter overall survival. Collectively, our findings establish HEATR1 as a novel regulator of AKT and a candidate predictive and prognostic indicator of drug responsiveness and outcome in PDAC patients.

UR - http://www.scopus.com/inward/record.url?scp=84958179019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958179019&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-0671

DO - 10.1158/0008-5472.CAN-15-0671

M3 - Article

C2 - 26676747

AN - SCOPUS:84958179019

VL - 76

SP - 572

EP - 581

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -